2. Metabolic Enzyme/Protease Apoptosis Autophagy NF-κB MAPK/ERK Pathway
  3. Endogenous Metabolite Apoptosis Autophagy Keap1-Nrf2 p38 MAPK Caspase
  4. Madecassoside

Madecassoside  (Synonyms: Asiaticoside A)

Cat. No.: HY-N0568 Purity: 99.58%
COA
SDS
Handling Instructions Technical Support

Madecassoside is a pentacyclic triterpene isolated from Centella asiatica and has anti-inflammatory properties. Antioxidant and anti-aging effects. Madecassoside is a pentacyclic triterpene isolated from Centella asiatica. Madecassoside is orally active and has inhibitory properties against inflammation, oxidation, apoptosis and autophagy. Madecassosid inhibits activities of p38 MAPK and NF-kB, exhibits an anti-apopototic property, activates Nrf2 expression to reduce the neurotoxicity. Madecassoside can be used in endocrine diseases, cardiovascular diseases, skin diseases and other diseases.

For research use only. We do not sell to patients.

CAS No. : 34540-22-2

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Madecassoside:

Madecassoside Related Antibodies

Top Publications Citing Use of Products
Cell Proliferation/Viability Assay
Bio/Physico-chemical Assay
WB
Histological Imaging/Staining

    Madecassoside purchased from MedChemExpress. Usage Cited in: Int J Pharm. 2025 Apr 12:125569.  [Abstract]

    Madecassoside at 10 μM and 15 μM promoted cell proliferation (P < 0.05), and the difference between 10 μM and 15 μM was statistically significant at 3 and 5 d (P < 0.05). On day 5, the promotion effect on the cells was the most obvious (P < 0.001).

    Madecassoside purchased from MedChemExpress. Usage Cited in: Int J Pharm. 2025 Apr 12:125569.  [Abstract]

    Relative protein expression of COL-I in HGFs after 1, 3, and 5 d of Madecassoside application at 5, 10, and 15 μM. The results showed that Madecassoside at 5 μM significantly increased the level of type I collagen in HGFs.

    Madecassoside purchased from MedChemExpress. Usage Cited in: J Biochem Mol Toxicol. 2025 Sep;39(9):e70509.  [Abstract]

    Effects of Madecassoside (MA, 30 mg/kg; i.p.; once daily for 4 weeks) on biochemical parameters of rats (after drug administration). These results indicate that MA relieves MN-induced renal dysfunctions in rats.

    Madecassoside purchased from MedChemExpress. Usage Cited in: J Biochem Mol Toxicol. 2025 Sep;39(9):e70509.  [Abstract]

    Renal tissues in sham, sham + Madecassoside (MA), model, and model + MA groups were investigated by staining with hematoxylin-eosin, PAS, and Masson and photographed by a light microscope. The results showed that Madecassoside (MA, 30 mg/kg; i.p.; once daily for 4 weeks) significantly improved the pathological condition of the mesangium and interstitium in rats with membranous nephropathy (MN), significantly reduced ECM deposition, and partially alleviated glomerular fibrosis lesions and interstitial dilation in rats.

    Madecassoside purchased from MedChemExpress. Usage Cited in: J Biochem Mol Toxicol. 2025 Sep;39(9):e70509.  [Abstract]

    Madecassoside (MA, 30 mg/kg; i.p.; once daily for 4 weeks) obviously restored these protein levels in membranous nephropathy (MN) rats.

    View All Endogenous Metabolite Isoform Specific Products:

    View All Isoforms
    Human Endogenous Metabolite Microbial Metabolite

    View All p38 MAPK Isoform Specific Products:

    View All Isoforms
    p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

    View All Caspase Isoform Specific Products:

    View All Isoforms
    Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Madecassoside is a pentacyclic triterpene isolated from Centella asiatica and has anti-inflammatory properties. Antioxidant and anti-aging effects. Madecassoside is a pentacyclic triterpene isolated from Centella asiatica. Madecassoside is orally active and has inhibitory properties against inflammation, oxidation, apoptosis and autophagy. Madecassosid inhibits activities of p38 MAPK and NF-kB[5][6], exhibits an anti-apopototic property, activates Nrf2 expression to reduce the neurotoxicity[10]. Madecassoside can be used in endocrine diseases, cardiovascular diseases, skin diseases and other diseases.

    In Vitro

    Madecassosid (30, 100 μmol/L, 12 h) increases cell viability of oxidative injuried human umbilical vein endothelial cells (HUVECs)[5].
    Madecassosid (10-100 μmol/L, 12 h) inhibits phosphorylation of p38 MAPK and activaty of Caspase-3, and therefore exhibits an antiapoptotic activity[5].
    Madecassosid (10-100 μg/L) exhibits anxioxidative activity against melanocyte dendtrites retraction, maintaining mitochondrial membrane potential and Ca2+ homeostasis[7].
    Madecassosid (30 μM) improves Insulin secretion by increasing expressions of p-IRS1, Akt and p-Akt under glucotoxic conditions[8].
    Madecassosid (10 μM, 24 h) prevents inflammation and autophagy of neuronal cells induced by Aβ25–35 through the class III PI3K/Beclin-1/Bcl-2 pathway[9].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Madecassoside Related Antibodies

    Cell Viability Assay[5]

    Cell Line: HUVECs
    Concentration: 10, 30, 100 μmol/L
    Incubation Time: 12 h
    Result: Increased cell viability to 68.9% and 78.3%, with concentration of 30 and 100 μmol/L, respectively.

    Western Blot Analysis[5]

    Cell Line: HUVECs
    Concentration: 10, 30, 100 μmol/L
    Incubation Time: 12 h
    Result: Inhibited phosphorylation in p38 MAPK.
    In Vivo

    Madecassosid (6, 12, 24 mg/kg, i.v.) resolves neurological deficit and ameliorates neuronal apoptosis after focal cerebral ischemia reperfusion[6].
    Madecassosid (6, 12, 24 mg/kg, i.v) inhibits activity of NF-kB and so prevents the brain injury[6].
    Madecassosid (120 mg/kg, i.g.) reduces LPS-induced neurotoxicity and enhances heme oxygenase proteins via upregulation of Nrf2 in LPS-stimulated neurotoxicity[10].
    Madecassosid (10-40 mg/kg,p.o.) ameliorates oxidative damage and imflammation after bleomycin (BLM) instillation, inhibits TGF-β1 overexpression and collagen synthesis, improves collagen degradation[11].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Focal cerebral ischemia reperfusion injury in Sprague Dawley rats[6]
    Dosage: 6, 12, 24 mg/kg
    Administration: Intravenous injection
    Result: Reduced neurological deficit, infarct area, brain damage and neuronal apoptosis.
    Animal Model: Lipopolysaccharide-induced neurotoxicity in Sprague-Dawley rats[10]
    Dosage: 30-120 mg/kg for 14 days
    Administration: Intraperitoneal injection
    Result: Reduced LPS-induced cognitive impairment and imflammatory cytokine, promoted Nrf2 pathway at concentration of 120 mg/kg.
    Clinical Trial
    Molecular Weight

    975.12

    Formula

    C48H78O20
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(C1(CCC(C)C2C)C2C3=CCC4C(C)(CC(O)C5C4(CC(O)C(O)C5(C)CO)C)C3(C)CC1)OC(C(C(O)C6O)O)OC6COC(C(C(O)C7OC(OC(C)C(O)C8O)C8O)O)OC7CO
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (102.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 33.33 mg/mL (34.18 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.0255 mL 5.1276 mL 10.2551 mL
    5 mM 0.2051 mL 1.0255 mL 2.0510 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (2.56 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (2.56 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.58%

    SDS (393 KB)

    COA (260 KB) HNMR (223 KB) LCMS (114 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 1.0255 mL 5.1276 mL 10.2551 mL 25.6379 mL
    5 mM 0.2051 mL 1.0255 mL 2.0510 mL 5.1276 mL
    10 mM 0.1026 mL 0.5128 mL 1.0255 mL 2.5638 mL
    15 mM 0.0684 mL 0.3418 mL 0.6837 mL 1.7092 mL
    20 mM 0.0513 mL 0.2564 mL 0.5128 mL 1.2819 mL
    25 mM 0.0410 mL 0.2051 mL 0.4102 mL 1.0255 mL
    30 mM 0.0342 mL 0.1709 mL 0.3418 mL 0.8546 mL
    DMSO 40 mM 0.0256 mL 0.1282 mL 0.2564 mL 0.6409 mL
    50 mM 0.0205 mL 0.1026 mL 0.2051 mL 0.5128 mL
    60 mM 0.0171 mL 0.0855 mL 0.1709 mL 0.4273 mL
    80 mM 0.0128 mL 0.0641 mL 0.1282 mL 0.3205 mL
    100 mM 0.0103 mL 0.0513 mL 0.1026 mL 0.2564 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Madecassoside Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Madecassoside34540-22-2Asiaticoside AEndogenous MetaboliteApoptosisAutophagyKeap1-Nrf2p38 MAPKCaspaseHUVECapoptosisautophagyCancerCardiovascular DiseaseEndocrinologyInflammationNeurological DiseaseSprague Dawley ratInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Madecassoside
    Cat. No.:
    HY-N0568
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.